hATTR Progression: Addressing Polyneuropathy
September 28, 2024 05:30pm
September 28, 2024 06:30pm
Industry Expert Theater I | Exhibit Hall
Join an AstraZeneca and Ionis sponsored program that reviews the key red flag symptoms and patient impact of hereditary Transthyretin-mediated amyloidosis or hATTR. This program will also provide an overview of a new therapy that can help address the progression of polyneuropathy in your patients.
Sponsored by AstraZeneca Ionis